Tool offers increased precision in estimating exacerbation risk Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. It is frequently seen in primary ...

Key opinion leaders highlight the triple therapy approach from the most recent GOLD guidelines, including ICS, long-acting beta-agonist (LABA), and long-acting muscarinic antagonist (LAMA). Jeffrey D.

Among patients with blood eosinophil counts greater than or equal to 150 cells/µL, the reduction in the annual rate of moderate to severe COPD exacerbations was found to be nominally significant. The ...

David Mannino is co-founder and chief medical officer of the COPD Foundation. He's an internal medicine doctor with a specialty in pulmonary, critical care, and sleep medicine at University of ...

The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...

COPD, or chronic obstructive pulmonary disease, is a group of life-changing lung diseases that include emphysema and chronic bronchitis. 1 Those living with COPD can experience coughing, wheezing, ...

Triple therapy in COPD significantly improves lung function vs LAMA monotherapy, LABA/LAMA, and ICS/LABA, although evidence showing this is often low quality. Triple therapy is likely effective, safe, ...

Effective treatment often requires you to take medications to better manage symptoms or stop taking medications if a doctor advises that you no longer need them. Finding the right dosages and ...

Triple therapy for COPD, vs ICS/LABA therapy, was independently associated with ischemic heart disease, heart failure, arrhythmia, and atrial fibrillation/flutter. Cardiovascular events in patients ...

Chronic obstructive pulmonary disease (COPD) makes it hard to breathe. Narrowed airways can make you cough, wheeze, and feel short of breath. It can affect how you exercise, work, and do other daily ...